When determining PE Ratios/EPS and other metrics the headline statutory NPAT is misleading due to a $1.92bn re-measurement gain on the merger with Saracen and other one off items. Refer to page 28 of the Annual Report as per below. I am using underlying NPAT to determine NST performance for FY21 which did not meet my expectations. This gives a PE Ratio of 10.99bn/0.3716bn = 29.57 based on Thursday's closing price of 9.44 per share and Earnings per share of 32 cents.
On the basis of this performance and their confusing/misleading reports to shareholders I have sold down 60% of my NST holdings and reallocated to NCM and EVN who have performed better in the last 12 months.
Mis-priced Stock, page-16
-
- There are more pages in this discussion • 717 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NST (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.81 |
Change
0.020(0.13%) |
Mkt cap ! $18.16B | |||
| Open | High | Low | Value | Volume |
| $15.64 | $15.85 | $15.61 | $43.85M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3784 | $15.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.81 | 6111 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| NST (ASX) Chart |